Payment overview · 2025
General Payments
$56.16
3 reported records · 2 companies
Healthcare provider profile · identity verified
Christopher K Iorio, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, IN · NPI 1467456285
Verified facts
What the public records show
CMS Open Payments records show Christopher K Iorio, MD received $56.16 in general payments during 2025 across 3 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 67.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 67.1% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $18.46 | 32.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $37.70 | 2 |
| Food and Beverage | $18.46 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 171 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
171 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 935 | 262 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 173 |
| Omeprazole | Omeprazole | 613 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 589 | 148 |
| Ipratropium Bromide | Ipratropium Bromide | 427 | 227 |
| Hydrochlorothiazide | Hydrochlorothiazide | 411 | 113 |
| Tramadol Hcl | Tramadol Hcl | 410 | 90 |
| Irbesartan | Irbesartan | 407 | 101 |
| Losartan Potassium | Losartan Potassium | 383 | 110 |
| Gabapentin | Gabapentin | 328 | 88 |
| Furosemide | Furosemide | 313 | 107 |
| Metformin Hcl | Metformin Hcl | 312 | 89 |
| Carvedilol | Carvedilol | 306 | 82 |
| Lisinopril | Lisinopril | 302 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 72 |
| Meloxicam | Meloxicam | 256 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 244 | 113 |
| Alendronate Sodium | Alendronate Sodium | 236 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 72 |
| Glimepiride | Glimepiride | 220 | 58 |
| Potassium Chloride | Potassium Chloride | 218 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 209 | 55 |
| Montelukast Sodium | Montelukast Sodium | 208 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 91 |
| Eliquis | Apixaban | 205 | 39 |
| Spironolactone | Spironolactone | 204 | 59 |
| Ezetimibe | Ezetimibe | 201 | 59 |
| Mounjaro | Tirzepatide | 201 | 32 |
| Sertraline Hcl | Sertraline Hcl | 197 | 55 |
| Simvastatin | Simvastatin | 192 | 51 |
| Prednisone | Prednisone | 186 | 123 |
| Trazodone Hcl | Trazodone Hcl | 177 | 54 |
| Jardiance | Empagliflozin | 171 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 44 |
| Doxazosin Mesylate | Doxazosin Mesylate | 156 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 146 | 116 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 142 | 37 |
| Synthroid | Levothyroxine Sodium | 134 | 32 |
| Mirtazapine | Mirtazapine | 129 | 50 |
| Allopurinol | Allopurinol | 126 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 37 |
| Bupropion Xl | Bupropion Hcl | 118 | 27 |
| Chlorthalidone | Chlorthalidone | 117 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 31 |
| Buspirone Hcl | Buspirone Hcl | 101 | 26 |
| Azelastine Hcl | Azelastine Hcl | 96 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 31 |
| Finasteride | Finasteride | 91 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 24 |
| Ozempic | Semaglutide | 90 | 18 |
| Pregabalin | Pregabalin | 84 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 25 |
| Donepezil Hcl | Donepezil Hcl | 82 | 29 |
| Famotidine | Famotidine | 81 | 26 |
| Fluconazole | Fluconazole | 81 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 60 |
| Trulicity | Dulaglutide | 74 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 24 |
| Alprazolam | Alprazolam | 68 | 12 |
| Atenolol | Atenolol | 68 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 15 |
| Diazepam | Diazepam | 65 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 30 |
| Estradiol | Estradiol | 62 | 23 |
| Lorazepam | Lorazepam | 61 | 19 |
| Warfarin Sodium | Warfarin Sodium | 61 | 17 |
| Hydrocortisone | Hydrocortisone | 60 | 36 |
| Celecoxib | Celecoxib | 57 | 20 |
| Memantine Hcl | Memantine Hcl | 55 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 15 |
| Cephalexin | Cephalexin | 54 | 42 |
| Mometasone Furoate | Mometasone Furoate | 54 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 12 |
| Farxiga | Dapagliflozin Propanediol | 53 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 13 |
| Mupirocin | Mupirocin | 52 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 14 |
| Metformin Hcl Er | Metformin Hcl | 49 | 18 |
| Torsemide | Torsemide | 49 | 12 |
| Valsartan | Valsartan | 49 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 16 |
| Midodrine Hcl | Midodrine Hcl | 48 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 48 | 47 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 36 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 27 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 29 |
| Nitroglycerin | Nitroglycerin | 38 | 24 |
| Cefuroxime | Cefuroxime Axetil | 37 | 32 |
| Klor-Con M20 | Potassium Chloride | 36 | 17 |
| Sucralfate | Sucralfate | 36 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Nystatin | Nystatin | 28 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 12 |
| Linzess | Linaclotide | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Glipizide | Glipizide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Indapamide | Indapamide | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Primidone | Primidone | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Klayesta | Nystatin | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Epinephrine | Epinephrine | 13 | 12 |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diflunisal | Diflunisal | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $56.16 · 3 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Arikayce, JARDIANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error